{
    "id": 533,
    "fullName": "MTOR wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type MTOR indicates that no mutation has been detected within the MTOR gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2475,
        "geneSymbol": "MTOR",
        "terms": [
            "MTOR",
            "FRAP",
            "FRAP1",
            "FRAP2",
            "RAFT1",
            "RAPT1",
            "SKS"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/13/2014",
    "updateDate": "06/11/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 251,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Hocena (antroquinonol) decreased the proliferation of NSCLC cells and decreased expression of Mtor (PMID: 21185843).",
            "molecularProfile": {
                "id": 592,
                "profileName": "MTOR wild-type"
            },
            "therapy": {
                "id": 985,
                "therapyName": "Antroquinonol",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 168,
                    "pubMedId": 21185843,
                    "title": "Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21185843"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3372,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torin 1 inhibited growth of transformed human cells expressing MTOR wild type in culture (PMID: 25295501).",
            "molecularProfile": {
                "id": 592,
                "profileName": "MTOR wild-type"
            },
            "therapy": {
                "id": 2247,
                "therapyName": "Torin 1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2388,
                    "pubMedId": 25295501,
                    "title": "Response and acquired resistance to everolimus in anaplastic thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25295501"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 592,
            "profileName": "MTOR wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}